Type 2 diabetes – case reports Case report series
Article Sidebar
Published:
Dec 31, 2015
Keywords:
type 2 diabetes, the treatment of diabetes, new hypoglycemic drugs, linagliptin, DPP4 inhibitor, hypoglycemia
Main Article Content
Abstract
For many years the treatment of type 2 diabetes was based primarily on the metformin and a sulfonylurea. If therapy with oral medication was not sufficient to achieve correct glycemic control, the next step was to include insulin therapy. The patient was afraid to change treatment, the need for injection and the risk of complications (especially the risk of hypoglycemia). Since the few years, the market offers a new oral hypoglycemic drugs, which allow patients to postpone the moment of including insulin treatment. In this work a few examples from clinical practice, wherein the normoglycemia is obtained through the use of DPP-4 inhibitor, were presented.
Article Details
How to Cite
Piątkiewicz, P. (2015). Type 2 diabetes – case reports. Medycyna Faktow (J EBM), 8(4(29), 14-21. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2278
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Blonde L., Dailey G.E., Jabbour S.A. et al.: Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformintablets: results of a retrospective cohort study. Curr. Med. Res. Opin. 2004; 20(4): 565-572.
2. Stanowisko Polskiego Towarzystwa Diabetologicznego. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2015. Diabetologia Kliniczna 2015; 4(supl. A).
3. Barnett A.H., Patel S., Harper R.: Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes. Metab. 2012; 14(12): 1145-1154.
4. Ross S.A., Caballero A.E., Del Prato S.: Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. Diabetes Obes. Metab. 2015; 17(2): 136-144.
5. Chelliah A., Burge M.R.: Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004; 21(8): 511-530.
6. Inzucchi S.E., Nauck M.A., Hehnke U. et al.: Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. Diabetes Obes. Metab. 2015; 17(9): 868-877.
7. Wang W., Yang J., Yang G. et al.: Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week, randomized clinical trial. J. Diabetes 2015, Mar 6 [doi: 10.1111/1753-0407.12284].
8. Yki-Järvinen H., Rosenstock J., Durán-Garcia S. et al.: Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52-week randomized, double-blind study. Diabetes Care. 2013; 36(12): 3875-3881.
9. Sheu W.H., Park S.W., Gong Y. et al.: Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 2015; 31(3): 503-512.
2. Stanowisko Polskiego Towarzystwa Diabetologicznego. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2015. Diabetologia Kliniczna 2015; 4(supl. A).
3. Barnett A.H., Patel S., Harper R.: Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes. Metab. 2012; 14(12): 1145-1154.
4. Ross S.A., Caballero A.E., Del Prato S.: Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. Diabetes Obes. Metab. 2015; 17(2): 136-144.
5. Chelliah A., Burge M.R.: Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004; 21(8): 511-530.
6. Inzucchi S.E., Nauck M.A., Hehnke U. et al.: Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. Diabetes Obes. Metab. 2015; 17(9): 868-877.
7. Wang W., Yang J., Yang G. et al.: Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week, randomized clinical trial. J. Diabetes 2015, Mar 6 [doi: 10.1111/1753-0407.12284].
8. Yki-Järvinen H., Rosenstock J., Durán-Garcia S. et al.: Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52-week randomized, double-blind study. Diabetes Care. 2013; 36(12): 3875-3881.
9. Sheu W.H., Park S.W., Gong Y. et al.: Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 2015; 31(3): 503-512.